Systematic analysis of COVID-19 mRNA vaccines using four orthogonal approaches demonstrates no excessive DNA impurities.

Systematic analysis of COVID-19 mRNA vaccines using four orthogonal approaches demonstrates no excessive DNA impurities.

Publication date: Dec 13, 2025

Despite substantial evidence for benefits of vaccination in mitigating the COVID-19 pandemic, the use of mRNA vaccines faces skepticism built on coincidental health events occurring after vaccination without proven causality. One of the claims regarding excessive amounts of residual DNA from the vaccine manufacturing process has arisen from misinterpretation of improperly conducted analyses. Here, we assessed the quantity, quality and identity of residual DNA in mRNA vaccines based on thoroughly performed and properly interpreted orthogonal methods, including qPCR, fluorometry, capillary electrophoresis and short-read DNA sequencing. Our results show that the quantity of residual DNA in all 15 analysed batches of Comirnaty and Spikevax vaccines is below approved limits and that it consists of small fragments originating from the template used to transcribe mRNA during vaccine production. We demonstrate that reliable mRNA vaccine analysis for DNA impurities requires rigorous application of well-controlled methods that minimise mutual interference of vaccine components.

Open Access PDF

Concepts Keywords
Covid Benefits
Fluorometry Covid
Misinterpretation Demonstrates
Reliable Evidence
Vaccines Excessive
Impurities
Mrna
Orthogonal
Quantity
Residual
Substantial
Systematic
Vaccination
Vaccine
Vaccines

Semantics

Type Source Name
disease MESH COVID-19
pathway REACTOME Reproduction
disease MESH included
disease MESH Park
disease MESH coronavirus infection
pathway REACTOME Translation
drug DRUGBANK Kanamycin
drug DRUGBANK Phenol
drug DRUGBANK Ethanol
drug DRUGBANK Water
disease MESH tumor
drug DRUGBANK Methionine
disease MESH strain
pathway REACTOME Digestion
drug DRUGBANK Aspartame
drug DRUGBANK Isoamyl alcohol
drug DRUGBANK Sodium acetate
drug DRUGBANK Medical air
disease MESH SBS
drug DRUGBANK Silicon dioxide
disease MESH infectious diseases
drug DRUGBANK Coenzyme M
disease MESH ICH
disease MESH Trisomy
pathway REACTOME Release
disease MESH RTT
disease MESH CCT
drug DRUGBANK 7-Methyl-Gpppa
drug DRUGBANK Timonacic
disease MESH CCA
disease MESH CAA
disease MESH ACC
drug DRUGBANK Trihexyphenidyl
drug DRUGBANK Thiocolchicoside
disease MESH TCC

Original Article

(Visited 4 times, 1 visits today)

Leave a Comment

Your email address will not be published. Required fields are marked *